A Study of the Quality of Life and Treatment Response to Once Weekly Epoetin Beta (Recormon) Treatment in Anemic Participants With Solid and Lymphoid Malignancies

Study at a glance

From the registry record, last updated by the sponsor on 2 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title

Quality of Life Related Response to Treatment in Anemic Cancer Patients Receiving Recormon and Efficacy of the Drug Dosage 30,000 IU Once Weekly in Patients With Lymphoproliferative Disorders

ClinicalTrials.gov ID

NCT00776425

Acronym / sponsor ID

ML20197

Conditions

Anemia

Phase

Phase 4

Study type

Interventional

Recruitment status

Completed

Enrolment

117 participants (actual)

Lead sponsor

Hoffmann-La RocheIndustry (pharma, biotech, devices)

Study start

Jan 2007

Primary completion

Nov 2012 (actual)

Study completion

Nov 2012 (actual)

First posted

21 Oct 2008 (estimated)

Results

Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose

Treatment

Allocation

Non-randomised

Intervention model

Parallel groups

Masking

None (open label)

Number of arms

2

Who may qualify

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Age groups

Adult, Older adult

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Primary outcome

1. Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment

   Time frame: 3-4 weeks

   Clinical response to epoetin beta is characterized as an increase of hemoglobin level by greater than or equal to (>=) 2 grams per liter (g/L) against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants who received 150 IU/kg and those received 30000 IU doses.

2. Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment

   Time frame: 6-8 weeks

   Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants who received 150 IU/kg and those received 30000 IU doses.

3. Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment

   Time frame: 10-12 weeks

   Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants who received 150 IU/kg and those received 30000 IU doses.

4. Percentage of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment with Mixed Dosing Regimen

   Time frame: 3-4 weeks

   Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants who received initial dose at 150 IU/kg and those received initial dose at 30000 IU/kg doses.

5. Percentage of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment with Mixed Dosing Regimen

   Time frame: 6-8 weeks

   Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants who received initial dose at 150 IU/kg and those received initial dose at 30000 IU/kg doses.

6. Percentage of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment with Mixed Dosing Regimen

   Time frame: 10-12 weeks

   Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants who received initial dose at 150 IU/kg and those received initial dose at 30000 IU/kg doses.

7. Quality of Life of Anemic Participants Using Short Form 36 (SF-36) Questionnaire Prior To Treatment

   Time frame: Baseline

   The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.

8. Quality of Life of Anemic Participants Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment

   Time frame: 3-4 Weeks

   The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.

9. Quality of Life of Anemic Participants Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment

   Time frame: 6-8 Weeks

   The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.

10. Quality of Life of Anemic Participants Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants.

11. Percentage of Participants With Quality of Life Integral Value (IV) Reduction Prior To Treatment

    Time frame: Baseline

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a population norm (nIV). The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minor reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Significant reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV).

12. Percentage of Participant With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minor reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Significant reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV).

13. Percentage of Participant With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minor reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Significant reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV).

14. Percentage of Participant With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minor reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Significant reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV).

15. Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    Quality of life related response to treatment was determined for each participant. Depending on the change of grade of the quality of life IV, quality of life related responses to treatment were characterized as improvement or stabilization.

16. Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    Quality of life related response to treatment was determined for each participant. Depending on the change of grade of the quality of life IV, quality of life related responses to treatment were characterized as improvement or stabilization.

17. Percentage of Participant With Characteristics of The Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Quality of life related response to treatment was determined for each participant. Depending on the change of grade of the quality of life IV, quality of life related responses to treatment were characterized as improvement or stabilization.

18. Fatigue Severity Score at Baseline

    Time frame: Baseline

    Fatigue was assessed by a digital rating scale (0 to 10) of MD Anderson Symptom Inventory (MDASI) cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

19. Fatigue Severity Score 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    Fatigue severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

20. Fatigue Severity Score 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    Fatigue severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

21. Fatigue Severity Score 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Fatigue severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

22. Percentage of Participant With Various Fatigue Severity Prior To Treatment

    Time frame: Baseline

    Fatigue was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

23. Percentage of Participant With Various Fatigue Severity 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    Fatigue was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

24. Percentage of Participant With Various Fatigue Severity 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    Fatigue was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

25. Percentage of Participant With Various Fatigue Severity 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Fatigue was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

26. Percentage of Participant With Different Symptoms Prior to Treatment (MDASI Questionnaire)

    Time frame: Baseline

    Percentage of participants with different symptoms (sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) of MDASI cancer participant symptom assessment questionnaire is presented.

27. Percentage of Participant With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 3-4 Weeks

    Percentage of participants with different symptoms (sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) of MDASI cancer participant symptom assessment questionnaire is presented.

28. Percentage of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 6-8 Weeks

    Percentage of participants with different symptoms (sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) of MDASI cancer participant symptom assessment questionnaire is presented.

29. Percentage of Participant With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 10-12 Weeks

    Percentage of participants with different symptoms (sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) of MDASI cancer participant symptom assessment questionnaire is presented.

30. Severity Score of Different Symptoms Prior toTreatment (MDASI Questionnaire)

    Time frame: Baseline

    Symptoms' type was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. Severity grades used for assessment of symptoms severity: 1) Minor symptom, score 1-4; 2) Moderate symptom: score 5-6 and Severe symptom: Score 7-10).

31. Severity Score of Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 3-4 weeks

    Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following severity grades were used for assessment of symptoms severity: 1) minor symptom, score 1-4; 2) moderate symptom: score 5-6; and 3) severe symptom: score 7-10.

32. Severity Score of Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 6-8 Weeks

    Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following severity grades were used for assessment of symptoms severity: 1) minor symptom, score 1-4; 2) moderate symptom: score 5-6; and 3) severe symptom: score 7-10.

33. Severity Score of Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 10-12 Weeks

    Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following severity grades were used for assessment of symptoms severity: 1) minor symptom, score 1-4; 2) moderate symptom: score 5-6; and 3) severe symptom: score 7-10.

34. Percentage of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Symptoms' type was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. Severity grades used for assessment of symptoms severity: 1) Minor symptom, score 1-4; 2) Moderate symptom: score 5-6 and Severe symptom: Score 7-10).

35. Percentage of Participants With Concomitant Symptoms of Various Severity Prior To Treatment

    Time frame: Baseline

    The number of concomitant symptoms was assessed in each participant. As a participant may concomitantly experience symptoms of various intensity, the following groups of participants were assessed based on the number and severity of symptoms: 1) >=7 moderate and severe symptoms (score >=5); 2) <7 moderate and severe symptoms; 3) Only mild symptoms (score 1-4).

36. Percentage of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    The number of concomitant symptoms was assessed in each participant. As a participant may concomitantly experience symptoms of various intensity, the following groups of participants were assessed based on the number and severity of symptoms: 1) >=7 moderate and severe symptoms (score >=5); 2) <7 moderate and severe symptoms; 3) Only mild symptoms (score 1-4).

37. Percentage of Participants With Concomitant Symptoms of Various Severity 4-6 Weeks After Start of Treatment

    Time frame: 4-6 weeks

    The number of concomitant symptoms was assessed in each participant. As a participant may concomitantly experience symptoms of various intensity, the following groups of participants were assessed based on the number and severity of symptoms: 1) >=7 moderate and severe symptoms (score >=5); 2) <7 moderate and severe symptoms; 3) Only mild symptoms (score 1-4).

38. Percentage of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    The number of concomitant symptoms was assessed in each participant. As a participant may concomitantly experience symptoms of various intensity, the following groups of participants were assessed based on the number and severity of symptoms: 1) >=7 moderate and severe symptoms (score >=5); 2) <7 moderate and severe symptoms; 3) Only mild symptoms (score 1-4).

39. Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire Prior To Treatment

    Time frame: Baseline

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

40. Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

41. Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 6-8 Weeks After Start of Treatment

    Time frame: 6-8 weeks

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

42. Quality of Life of Anemic Participants With Clinical Response Using SF-36 Questionnaire 10-12 Weeks After Start of Treatment

    Time frame: 10-12 weeks

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

43. Percentage of Participants With Different Symptoms Who Had Clinical Response Prior to Treatment

    Time frame: Baseline

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, grief, appetite disorders, and numbness) who had clinical response is presented. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L with no blood transfusions within the 6 previous weeks.

44. Percentage of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, grief, appetite disorders, and numbness) who had clinical response is presented. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks.

45. Percentage of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment

    Time frame: 6-8 weeks

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, grief, appetite disorders, and numbness) who had clinical response is presented. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks.

46. Percentage of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment

    Time frame: 10-12 weeks

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, grief, appetite disorders, and numbness) who had clinical response is presented. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks.

47. Severity Score of Different Symptoms in Anemic Participants With Clinical Response Prior To Treatment

    Time frame: Baseline

    Severity grades on a scale of 0-10, were used for assessment of symptoms severity: 1) Minor symptom, score 1-4; 2) Moderate symptom: score 5-6 and Severe symptom: Score 7-10). Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

48. Severity Score of Different Symptoms in Anemic Participants With Clinical Response 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    Severity grades on a scale of 0-10 were used for assessment of symptoms severity. The following severity grades were used: 1) Minor symptom: score 1-4; 2) Moderate symptom: score 5-6; and 3) Severe symptom: score 7-10. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

49. Severity Score of Different Symptoms in Anemic Participants With Clinical Response 6-8 Weeks After Start of Treatment

    Time frame: 6-8 weeks

    Severity grades on a scale of 0-10 were used for assessment of symptoms severity. The following severity grades were used: 1) Minor symptom: score 1-4; 2) Moderate symptom: score 5-6; and 3) Severe symptom: score 7-10. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

50. Severity Score of Different Symptoms in Anemic Participants With Clinical Response 10-12 Weeks After Start of Treatment

    Time frame: 10-12 weeks

    Severity grades on a scale of 0-10 were used for assessment of symptoms severity. The following severity grades were used: 1) Minor symptom: score 1-4; 2) Moderate symptom: score 5-6; and 3) Severe symptom: score 7-10. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >=2 g/L against baseline with no blood transfusions within the 6 previous weeks.

51. Percentage of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose

    Time frame: 3-4 Weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

52. Percentage of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose

    Time frame: 6-8 Weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

53. Percentage of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose

    Time frame: 10-12 Weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results were presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

54. Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) Prior to Treatment

    Time frame: Baseline

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

55. Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

56. Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

57. Quality of Life in Anemic Participants Receiving Treatment at 30000 IU Once Weekly (SF-36 Questionnaire) 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    The SF-36 evaluates 36 questions related to participant-rated quality of life using 7 domains: physical and social functioning, physical and emotional role limitations, overall health, vitality, and mental health. The total score is the average of the individual question scores, which is scaled from 0 to 100, with higher scores indicating better functioning. The mean score at each timepoint was determined by averaging the scores among all participants. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

58. Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction Prior to Treatment

    Time frame: Baseline

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minimal reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Severe reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV). Results are presented for participants with lymphoproliferative disorders and solid tumors.

59. Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minimal reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Severe reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV). Results are presented for participants with lymphoproliferative disorders and solid tumors.

60. Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minimal reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Severe reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV). Results are presented for participants with lymphoproliferative disorders and solid tumors.

61. Number of Participants With Lymphoproliferative Disorders and Solid Tumors Who Had Quality of Life IV Reduction 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minimal reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Severe reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV). Results are presented for participants with lymphoproliferative disorders and solid tumors.

62. Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Prior Receiving Treatment at 30000 IU Once Weekly

    Time frame: Baseline

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results were presented for participants with lymphoproliferative disorders (LD) and solid tumors (STS) who received 30000 IU dose.

63. Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly

    Time frame: 3-4 weeks

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results were presented for participants with lymphoproliferative disorders (LD) and solid tumors (STS) who received 30000 IU dose.

64. Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly

    Time frame: 6-8 weeks

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results were presented for participants with lymphoproliferative disorders (LD) and solid tumors (STS) who received 30000 IU dose.

65. Percentage of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly

    Time frame: 10-12 Weeks

    Percentage of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results were presented for participants with lymphoproliferative disorders (LD) and solid tumors (STS) who received 30000 IU dose.

66. Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors Prior to Treatment at 30000 IU Once Weekly

    Time frame: Baseline

    Severity grades on a scale of 0-10 were used for assessment of symptoms severity. The following severity grades were used: 1) Minor symptom: score 1-4; 2) Moderate symptom: score 5-6; and 3) Severe symptom: score 7-10. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

67. Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly

    Time frame: 3-4 weeks

    Severity grades on a scale of 0-10 were used for assessment of symptoms severity. The following severity grades were used: 1) Minor symptom: score 1-4; 2) Moderate symptom: score 5-6; and 3) Severe symptom: score 7-10. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

68. Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly

    Time frame: 6-8 weeks

    Severity grades on a scale of 0-10 were used for assessment of symptoms severity. The following severity grades were used: 1) Minor symptom: score 1-4; 2) Moderate symptom: score 5-6; and 3) Severe symptom: score 7-10. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

69. Severity Score of Different Symptoms in Participants With Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly

    Time frame: 10-12 weeks

    Severity grades on a scale of 0-10 were used for assessment of symptoms severity. The following severity grades were used: 1) Minor symptom: score 1-4; 2) Moderate symptom: score 5-6; and 3) Severe symptom: score 7-10. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

70. Percentage of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Severity grades on a scale of 0-10, were used for assessment of symptoms severity: 1) Minor symptom, score 1-4; 2) Moderate symptom: score 5-6 and 3) Severe symptom: Score 7-10. Results were presented for participants with lymphoproliferative disorders (LD) and solid tumors (STS) who received 30000 IU dose.

71. Number of Participants Who Achieved a Clinical Response 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by greater than or equal to (>=) 2 grams per liter (g/L) against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants who received 150 IU/kg and those received 30000 IU doses.

72. Number of Participants Who Achieved a Clinical Response 6-8 Weeks After Start of Treatment

    Time frame: 6-8 weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants who received 150 IU/kg and those received 30000 IU doses.

73. Number of Participants Who Achieved a Clinical Response 10-12 Weeks After Start of Treatment

    Time frame: 10-12 weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants who received 150 IU/kg and those received 30000 IU doses.

74. Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants who received initial dose at 150 IU/kg and those received initial dose at 30000 IU/kg doses.

75. Number of Participants Who Achieved a Clinical Response With Mixed Drug Dosing Regimen, 6-8 Weeks After Start of Treatment

    Time frame: 6-8 weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants who received mixed dosing regimen with initial dose at 150 IU/kg and those received initial dose at 30000 IU/kg doses.

76. Number of Participants Who Achieved a Clinical Response With Mixed Dosing Regimen, 10-12 Weeks After Start of Treatment

    Time frame: 10-12 weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants who received mixed dosing regimen with initial dose at 150 IU/kg and those received initial dose at 30000 IU/kg doses.

77. Number of Participants With Quality of Life IV Reduction 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minor reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Significant reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV).

78. Number of Participants With Quality of Life IV Reduction 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minor reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Significant reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV).

79. Number of Participants With Quality of Life IV Reduction 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    A scale of the quality of life IV was developed for stratification of participants depending on the degree of lowering of the quality of life. The analysis has been performed based on the quality of life IV of a participant with a nIV. The following grades of the quality of life IV reduction were determined: 1) No quality of life reduction (no differences between participant IV and nIV); 2) Minor reduction of the IV quality of life (IV reduction at <25% of nIV); 3) Moderate reduction of the IV quality of life (IV reduction at 25-50% of nIV); 4) Significant reduction of the IV quality of life (IV reduction at 51-75% of nIV); 5) Critical reduction of the IV quality of life (IV reduction at >75% of nIV).

80. Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    Quality of life related response to treatment was determined for each participant. Depending on the change of grade of the quality of life IV, quality of life related responses to treatment were characterized as improvement or stabilization. Quality of life related responses to treatment was characterized as stabilization if no changes in the quality of life IV were observed. Quality of life related responses to treatment was characterized as improvement when quality of life IV was changed positively (positive changes in the quality of life IV).

81. Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    Quality of life related response to treatment was determined for each participant. Depending on the change of grade of the quality of life IV, quality of life related responses to treatment were characterized as improvement or stabilization. Quality of life related responses to treatment was characterized as stabilization if no changes in the quality of life IV were observed. Quality of life related responses to treatment was characterized as improvement when quality of life IV was changed positively (positive changes in the quality of life IV).

82. Number of Participants With Characteristics of the Quality of Life Related Response To Treatment 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Quality of life related response to treatment was determined for each participant. Depending on the change of grade of the quality of life IV, quality of life related responses to treatment were characterized as improvement or stabilization. Quality of life related responses to treatment was characterized as stabilization if no changes in the quality of life IV were observed. Quality of life related responses to treatment was characterized as improvement when quality of life IV was changed positively (positive changes in the quality of life IV).

83. Percentage of Participants With Various Fatigue Severity 3-4 Weeks After Start of Treatment

    Time frame: 3-4 Weeks

    Fatigue severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

84. Percentage of Participants With Various Fatigue Severity 6-8 Weeks After Start of Treatment

    Time frame: 6-8 Weeks

    Fatigue severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

85. Percentage of Participants With Various Fatigue Severity 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Fatigue severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following fatigue grades were used: 1) Mild fatigue: score 1-3; 2) Moderate fatigue: score 4-6; 3) Severe fatigue: score 7-10. Score 1-3 fatigue was classified as insignificant; score 4-10 fatigue was assessed as significant.

86. Number of Participants With Different Symptoms 3-4 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 3-4 Weeks

    Number of participants with different symptoms (sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) of MDASI cancer participant symptom assessment questionnaire is presented. Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. Participants were asked to rate severity of each symptom; each item rated from 0 to 10, with 0 = symptom not present and 10 = severe symptom.

87. Number of Participant With Different Symptoms 6-8 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 6-8 Weeks

    Number of participants with different symptoms (sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) of MDASI cancer participant symptom assessment questionnaire is presented. Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. Participants were asked to rate severity of each symptom; each item rated from 0 to 10, with 0 = symptom not present and 10 = severe symptom.

88. Number of Participants With Different Symptoms 10-12 Weeks After Start of Treatment (MDASI Questionnaire)

    Time frame: 10-12 Weeks

    Number of participants with different symptoms (sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) of MDASI cancer participant symptom assessment questionnaire is presented. Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. Participants were asked to rate severity of each symptom; each item rated from 0 to 10, with 0 = symptom not present and 10 = severe symptom.

89. Number of Participants With Improvement in Symptoms Severity 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following severity grades were used for assessment of symptoms severity: 1) minor symptom: score 1-4; 2) moderate symptom: score 5-6; and 3) severe symptom: score 7-10. Participants who had a reduction in scores from moderate-to-severe to mild were considered improved.

90. Number of Participants With Concomitant Symptoms of Various Severity 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    The number of concomitant symptoms was assessed in each participant. As a participant may concomitantly experience symptoms of various intensity, the following groups of participants were assessed based on the number and severity of symptoms: 1) >=7 moderate and severe symptoms (score >=5); 2) <7 moderate and severe symptoms (score >=5); 3) Only mild symptoms (score 1-4).

91. Number of Participants With Concomitant Symptoms of Various Severity 6-8 Weeks After Start of Treatment

    Time frame: 6-8 weeks

    The number of concomitant symptoms was assessed in each participant. As a participant may concomitantly experience symptoms of various intensity, the following groups of participants were assessed based on the number and severity of symptoms: 1) >=7 moderate and severe symptoms (score >=5); 2) <7 moderate and severe symptoms (score >=5); 3) Only mild symptoms (score 1-4).

92. Number of Participants With Concomitant Symptoms of Various Severity 10-12 Weeks After Start of Treatment

    Time frame: 10-12 Weeks

    The number of concomitant symptoms was assessed in each participant. As a participant may concomitantly experience symptoms of various intensity, the following groups of participants were assessed based on the number and severity of symptoms: 1) >=7 moderate and severe symptoms (score >=5); 2) <7 moderate and severe symptoms (score >=5); 3) only mild symptoms (score 1-4).

93. Number of Participants With Different Symptoms Who Had Clinical Response 3-4 Weeks After Start of Treatment

    Time frame: 3-4 weeks

    Number of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, grief, appetite disorders, and numbness) who had clinical response is presented. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks.

94. Number of Participants With Different Symptoms Who Had Clinical Response 6-8 Weeks After Start of Treatment

    Time frame: 6-8 weeks

    Number of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, grief, appetite disorders, and numbness) who had clinical response is presented. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks.

95. Number of Participants With Different Symptoms Who Had Clinical Response 10-12 Weeks After Start of Treatment

    Time frame: 10-12 weeks

    Number of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, grief, appetite disorders, and numbness) who had clinical response is presented. Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks.

96. Number of Participants With Clinical Response After First 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose

    Time frame: 3-4 Weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

97. Number of Participants With Clinical Response After Second 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose

    Time frame: 6-8 Weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

98. Number of Participants With Clinical Response After Third 3-4 Weeks of Treatment at 30000 IU Once Weekly Dose

    Time frame: 9-12 Weeks

    Clinical response to epoetin beta is characterized as an increase of hemoglobin level by >= 2 g/L against baseline with no blood transfusions within the 6 previous weeks. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

99. Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors Before Receiving Treatment at 30000 IU Once Weekly

    Time frame: Baseline

    Number of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

100. Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 3-4 Weeks After Start of Treatment at 30000 IU Once Weekly

     Time frame: 3-4 weeks

     Number of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

101. Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 6-8 Weeks After Start of Treatment at 30000 IU Once Weekly

     Time frame: 6-8 weeks

     Number of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

102. Number of Participants With Different Symptoms Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly

     Time frame: 10-12 Weeks

     Number of participants with different symptoms (fatigue, sleep disorders, depressed mood, lethargy, numbness, appetite disorders, and grief) is presented. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

103. Number of Participants With Improvement in Symptoms Severity Categorized by Lymphoproliferative Disorders and Solid Tumors 10-12 Weeks After Start of Treatment at 30000 IU Once Weekly

     Time frame: 10-12 Weeks

     Number of participants with improvement in different symptoms (fatigue, depressed mood, sleep disorders, appetite disorders, lethargy, grief, and numbness) is presented. Symptoms' severity was assessed by a digital rating scale (0 to 10) of MDASI cancer participant symptom assessment questionnaire. The following severity grades were used for assessment of symptoms severity: 1) minor symptom: score 1-4; 2) moderate symptom: score 5-6; and 3) severe symptom: score 7-10. Participants who had a reduction in scores from moderate-to-severe to mild were considered improved. Results are presented for participants with lymphoproliferative disorders and solid tumors who received 30000 IU dose.

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

• Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2017.

Related trials for Anemia

• RecruitingPhase 1/2

  The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia

  Aplastic Anemia, Refractory

• Active, not recruitingPhase 1

  A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

  Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy

• Not yet recruitingObservational study

  Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme

  Cardiac Surgical Procedures, Blood Transfusion

• RecruitingPhase 1/2

  Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

  Myelodysplastic Syndromes

• RecruitingObservational study

  Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

  Fanconi Anemia, Inherited Bone Marrow Failure Syndrome

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

22 sites in 1 country: see every site and its status.